Sionna Therapeutics, Inc. (SION) Stock Forecast
SION analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.33 / 5 from 12 analysts
- Price target
- $21.00 average of analyst targets
- Upside to target
- +439.8% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.62
- 52-week range
- $3.89 – $51.04
SION analyst ratings
12 analystsNumber of analysts at each rating.
SION price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SION earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.68 | −$0.84 | −$0.53 | −$0.46 | −47.3% | 8 |
| Current fiscal year (2026) | −$2.45 | −$2.64 | −$1.93 | −$1.88 | −30.1% | 10 |
| Next fiscal year (2027) | −$2.23 | −$3.18 | −$1.24 | −$2.45 | +8.8% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SION revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 10 |
SION EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SION EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.65 | −$0.65 | −$0.67 | −$0.67 | −$0.68 | +4.1% | 2 up · 1 down |
| Current fiscal year (2026) | −$2.54 | −$2.54 | −$2.56 | −$2.56 | −$2.45 | −3.9% | 2 up · 1 down |
| Next fiscal year (2027) | −$2.80 | −$2.80 | −$2.53 | −$2.53 | −$2.23 | −20.4% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SION earnings surprises
Reported EPS vs the consensus estimate for the last 7 quarters; SION beat in 3 of 7.
What analysts expect from SION
12 analysts cover Sionna Therapeutics; their consensus rating is hold (3.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.00, 439.8% above the latest close of $3.89. Analysts expect earnings of −$2.45 per share for 2026, −30.1% from a year earlier. For 2027 the average estimate is −$2.23 per share. Sionna Therapeutics beat the EPS estimate in 3 of the last 7 quarters.
Related: SION income statement, SION key metrics, SION chart. See the SION stock overview for the latest quote and news.
SION forecast FAQ
What is Sionna Therapeutics's price target?
The average analyst price target for Sionna Therapeutics is $21.00, 439.8% above the latest close of $3.89.
Is Sionna Therapeutics a buy, hold or sell?
Of 12 analysts covering Sionna Therapeutics, 2 rate it a strong buy, 0 a buy, 10 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Sionna Therapeutics's EPS forecast?
Analysts forecast −$2.45 per share for 2026 (range −$2.64 to −$1.93); for 2027 the estimate is −$2.23.
When does Sionna Therapeutics report earnings?
Sionna Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.62.
Does Sionna Therapeutics usually beat earnings estimates?
Sionna Therapeutics reported EPS at or above the analyst estimate in 3 of the last 7 quarters.